Zobrazeno 1 - 10
of 15
pro vyhledávání: '"S. S. Couto"'
Autor:
S. S. Couto, Richard A Lecouteur, Beverly K. Sturges, Peter F Moore, Karen M. Vernau, Robert Higgins, Stephanie Kube, Peter J Dickinson
Publikováno v:
Veterinary Pathology. 45:336-346
An acute to chronic idiopathic necrotizing meningoencephalitis was diagnosed in 5 Chihuahua dogs aged between 1.5 and 10 years. Presenting neurologic signs included seizures, blindness, mentation changes, and postural deficits occurring from 5 days t
Publikováno v:
Veterinary pathology. 49(1)
Neoplasia in both animals and humans results in part from lasting activation of tumor-promoting genes (“oncogenes”) or diminished function of genes responsible for preventing neoplastic induction (“tumor suppressor genes”). The concept of “
Publikováno v:
Veterinary and comparative oncology. 6(3)
P-glycoprotein (Pgp) is a transmembrane protein pump involved in drug resistance in canine and human lymphoma. There are no published clinical studies evaluating Pgp expression in feline lymphoma. The purpose of this study is to evaluate the level of
Autor:
C. A. Artacho, S. S. Couto
Publikováno v:
Veterinary pathology. 44(4)
Mycobacterium fortuitum is a saprophytic, fast-growing, nontuberculous, and nonlepromatous mycobacterium that can cause infections in animals and humans. In dogs and cats, it is one of the most common agents of ulcerative dermatitides and panniculiti
Publikováno v:
Veterinary pathology. 39(1)
Forty-four primary feline vaccine-associated fibrosarcomas and 16 recurrences were examined histologically for detailed morphologic characterization with emphasis on tumor grade, presence of neoplastic multinucleated giant cells, presence and proport
Publikováno v:
Veterinary pathology. 37(6)
Actinomyces sp. are commensal, filamentous, gram-positive, acid-fast-negative bacteria that can cause pyogranulomatous inflammation in animals and humans. Central nervous system (CNS) disease is a rare presentation of actinomycosis and is usually due
Autor:
Silveira AM; Pulmonology Department, Fernando Fonseca Hospital, Amadora, Portugal., Gaspar Â; Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal., Benito-Garcia F; Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal., Couto S; Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal., Matias J; Pediatric Department, Garcia de Orta Hospital, Almada, Portugal., Chambel M; Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal., Morais-Almeida M; Immunoallergy Department, CUF Descobertas Hospital, Lisbon, Portugal.
Publikováno v:
Journal of investigational allergology & clinical immunology [J Investig Allergol Clin Immunol] 2019; Vol. 29 (4), pp. 311-313. Date of Electronic Publication: 2019 Apr 08.
Autor:
Mayor TS; Laboratory for Physiology and Protection, Swiss Federal Laboratories for Materials Science and Technology, Empa, Lerchenfeldstrasse 5, 9014, St. Gallen, Switzerland. tiago.sottomayor@empa.ch., Couto S; Product Optimization and Characterization Laboratory, CeNTI, Centre for Nanotechnology and Smart Materials, Rua Fernando Mesquita, 2785, 4760-034, Vila Nova de Famalicão, Portugal., Psikuta A; Laboratory for Physiology and Protection, Swiss Federal Laboratories for Materials Science and Technology, Empa, Lerchenfeldstrasse 5, 9014, St. Gallen, Switzerland., Rossi RM; Laboratory for Physiology and Protection, Swiss Federal Laboratories for Materials Science and Technology, Empa, Lerchenfeldstrasse 5, 9014, St. Gallen, Switzerland.
Publikováno v:
International journal of biometeorology [Int J Biometeorol] 2015 Dec; Vol. 59 (12), pp. 1875-89. Date of Electronic Publication: 2015 May 21.
Autor:
Bjorklund CC; Translational Development, Celgene Corporation, Summit, NJ, USA., Lu L; Translational Development, Celgene Corporation, Summit, NJ, USA., Kang J; Translational Development, Celgene Corporation, Summit, NJ, USA., Hagner PR; Translational Development, Celgene Corporation, Summit, NJ, USA., Havens CG; Translational Development, Celgene Corporation, Summit, NJ, USA., Amatangelo M; Translational Development, Celgene Corporation, Summit, NJ, USA., Wang M; Celgene Corporation, San Diego, CA, USA., Ren Y; Celgene Corporation, San Diego, CA, USA., Couto S; Celgene Corporation, San Diego, CA, USA., Breider M; Celgene Corporation, San Diego, CA, USA., Ning Y; Celgene Corporation, San Diego, CA, USA., Gandhi AK; Translational Development, Celgene Corporation, Summit, NJ, USA., Daniel TO; Translational Development, Celgene Corporation, Summit, NJ, USA., Chopra R; Translational Development, Celgene Corporation, Summit, NJ, USA., Klippel A; Translational Development, Celgene Corporation, Summit, NJ, USA., Thakurta AG; Translational Development, Celgene Corporation, Summit, NJ, USA.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2015 Oct 02; Vol. 5, pp. e354. Date of Electronic Publication: 2015 Oct 02.
Autor:
Ocio EM; 1] Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain [2] Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Fernández-Lázaro D; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., San-Segundo L; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., López-Corral L; Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain., Corchete LA; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Gutiérrez NC; 1] Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain [2] Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Garayoa M; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Paíno T; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., García-Gómez A; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Delgado M; 1] Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain [2] Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Montero JC; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Díaz-Rodríguez E; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Mateos MV; 1] Hospital Universitario de Salamanca, IBSAL, Salamanca, Spain [2] Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Pandiella A; Centro de Investigación del Cáncer-IBMCC, Universidad de Salamanca-CSIC, Salamanca, Spain., Couto S; Celgene Corporation, Summit, NJ, USA., Wang M; Celgene Corporation, Summit, NJ, USA., Bjorklund CC; Celgene Corporation, Summit, NJ, USA., San-Miguel JF; Clínica Universidad de Navarra, Centro de Investigaciones Médicas Aplicadas (CIMA), Pamplona, Spain.
Publikováno v:
Leukemia [Leukemia] 2015 Mar; Vol. 29 (3), pp. 705-14. Date of Electronic Publication: 2014 Aug 08.